The definitive intelligence hub for biopharmaceuticals, clinical developments, stock market indicators, and biotechnology careers.
Abbott said the FDA has approved new capabilities for its CardioMEMS HF System, an implantable remote-monitoring sensor for heart failure patients designed to help them take a more active role in managing their condition.
Biogen reported new durability data for its lupus treatment in cutaneous (skin) disease, a result that strengthens the case for its sizable investment in the program.
BridgeBio is turning to YouTube and partnerships with hip-hop and public-health voices for a new campaign aimed at raising awareness of ATTR-CM, the rare heart condition treated by its drug Attruby.
CSL has agreed to pay up to $1.6 billion to co-develop an Alentis Therapeutics drug for autoimmune disease, pairing the Australian company's commercial reach with a claudin-targeting candidate.
The FDA said it is seeking public input as part of an effort to support research into ibogaine, a psychedelic compound being studied for addiction and other psychiatric uses.
Genentech has signed a deal worth up to $1.27 billion to license a preclinical blood-brain barrier asset from Alector, adding to its neurology pipeline.
The 2026 Nobel Prize in Physiology or Medicine has been awarded to a trio of scientists for the discovery of optogenetics, a light-based method for switching neurons on and off that has become a foundational research tool in neuroscience.
Novo Nordisk said its U.S. review of a hemophilia candidate has been extended after the FDA flagged corrections needed at a manufacturing site, pushing back a potential approval decision.
OMLYCLO (omalizumab-igec), described as the first and only FDA-approved interchangeable biosimilar to Xolair, is now commercially available in the United States.
Shionogi has agreed to acquire rare-disease specialist IntraBio for about $2 billion, extending the Japanese drugmaker's push beyond its core anti-infective business into neurology.
Access to addiction meds for young people has improved — but retention hasn’t
Adecto blames ‘risk-adverse funding environment’ for closing
An Ebola treatment center was burned down as the death toll in Congo passes 4,000
Bayer doubles down on US with $2.2B Ohio manufacturing project
Bayer taps new chief medical officer—Chutes & Ladders
BMO most bullish on Merck’s, bearish on BMS’ plans to contend with patent cliffs
Buzzy AI biotech Xaira unveils antibody platform ambitions
Everlywell rolls out Clairity AI for breast cancer in US
Lilly’s BTK drug Jaypirca enters first-line CLL
Locking in on pharma’s consumerization trend
New diabetes and obesity studies making waves at EASD
NIH rolling out streamlined website to help public find information more easily
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
Teva, Samsung Bioepis deepen biosimilar bonds with new deal
UK puts £80m behind dementia diagnosis push
Analysts unshaken by patient death in BMS lung fibrosis trial
Asahi Kasei wraps years of global dealmaking into a single brand
Avanos Medical, Inc. Launches Game Ready Over-the-Counter Recovery System in the U.S.
Bayer names Christoph Koenen as its new CMO
BMS reports liver injury events in lung disease program, with key readout near
BTL Expands EXOMIND Platform with New FDA Clearances
Clear Scientific Reports Positive Phase 2 Results for CS-1103, the First Investigational Therapeutic That Removes Fentanyl from the Body
FDA Approves First Heart Valve Designed to Grow with Children
Foghorn lays off 40% of staff after Lilly collaboration ends
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
Genentech amplifies breast cancer conversations in new campaign
Genentech's CEO on the next 50 years of the original biotech
GLOBE model finalised, with narrowed scope and fewer savings
GORE ANNOUNCES FIRST PATIENT ENROLLMENT IN THE GORE EXCLUDER IBE PLUS STENT GRAFT PIVOTAL STUDY
Imbed Biosciences' DualGuard Silver-Gallium Matrix Safety Study Now Registered on ClinicalTrials.gov
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
Lilly dives deep into Foundayo's cardio perks in T2D, obesity
M&A slows in Q3 but Vertex snags one of the year's biggest in $10B Crinetics buy
MavriX Bio Announces FDA Rare Pediatric Disease Designation for Investigational MVX-220 for the Treatment of Angelman Syndrome
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
NICE backs Sobi's Tryngolza for rare disease FCS
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
PearlMatrix® P-15 Peptide Enhanced Bone Graft Receives Medicare New Technology Add-on Payment (NTAP), Helping Hospitals Accelerate Lumbar Fusion
Real Chemistry adds MaestroHCP to conduct omnichannel campaigns
Recruiters see 'signs of recovery' as biotech layoffs stay cool
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent
Taiho ph. 3 win sets up potential oral franchise expansion
Top journal’s special issue on women’s health casts spotlight on menopause and pain
US government launches AI-driven programs to overhaul clinical trials
Zealand slides as Boehringer-partnered obesity drug underwhelms
$40M in tax incentives expected to generate 1,600+ life sciences jobs in Massachusetts
Alnylam drafts football veteran for heart disease education push
Amgen reveals 6-point drop in lupus severity behind ph. 2 win
Apogee buy delivers eczema trial win for AbbVie
Atara, Pierre Fabre resubmit twice-rebuffed cell therapy after FDA flips again
Beam sues rival startup, claims former scientist stole secrets
BioMarin lays off 117 California workers to consolidate footprint
Connect drug reduces COPD attacks 85%, misses a secondary goal
FDA ACCEPTS NEW DRUG APPLICATION FOR CELECOR'S INVESTIGATIONAL HEART-ATTACK DRUG
FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committees
FIRE1 Announces First Patient Implant in the NORM-HF Pivotal Trial Evaluating a New Physiologic Approach to Heart Failure Management
Gluware Extends Its Automation Platform Beyond the Network to Connected Medical Devices
GSK continues stockpiling Wave drugs with liver-focused program
Highlight Therapeutics illuminates positive data in skin cancer
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
Lilly reported that its investigational EloraTZP combination of eloralintide and tirzepatide delivered greater weight loss and A1c reduction than tirzepatide 15 mg alone in adults with obesity and type 2 diabetes.
Lilly sets up next-gen obesity war with phase 3 retatrutide data
Medtronic announces regulatory milestones for newest cardiac mapping and ablation software
Merck's anti-TL1A secures a ph. 2 hidradenitis suppurativa win
Newronika Announces First Participant Implanted in ADVENT Pivotal Study
Novo is handing out pink slips to 108 staffers in New Jersey
Organon phones home with sci-fi themed Vtama campaign
PhRMA hires ex-House Majority Leader Eric Cantor as its CEO
Pierre Fabre Pharmaceuticals Resubmits Tabelecleucel Biologics License Application for Treatment of Epstein-Barr Virus Positive-Post-Transplant Lymphoproliferative Disease to the FDA
Radiopharmaceutical player NorthStar locks up $185M
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose
Superior weight loss, blood sugar control propel Lilly's amylin-GIP/GLP-1 combo into Phase 3
Trend of women-led M&A fades in 2026 with just two deals so far
Two men charged with infiltrating fake Ozempic into US
UPSHER-SMITH LAUNCHES FLUVOXAMINE MALEATE EXTENDED-RELEASE CAPSULES
Varda series D brings $251M for space-based drug production
VEMERIX Launches Patented Single-Use Ultrasound Guidance Puncture Kit With Probe-Matched Customization
AbbVie wins FDA approval for Parkinson's drug from $8.7B Cerevel takeover
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
ai3Bio buzzing with $48M for STING pathway targeting pipeline
Audien beams up William Shatner to boldly boost hearing aid biz
Australia's CSL taps Amazon's cloud unit to boost research pipeline
BiomEdit's First-of-its-Kind Engineered Bacterial Biologic for Poultry Receives Conditional Licensure from USDA
Canadian $5M clinical trial program cuts start-up to 45 days
Cepheid Receives FDA Clearance for Xpert® Respiratory Panel to Aid in the Diagnosis of Respiratory Tract Infection
Cytrellis Announces Partnership for Commercialization of ellacor® Micro-Coring® Technology in South Korea
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
FastWave Medical Reports 96.4% Procedural Success in First-in-Human Study of Sola™ Coronary Laser IVL System
FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme
Implantica's RefluxStop® U.S. market launch kicked off at the 2026 American Foregut Society Meeting, receiving an outstanding reception
Inizio Evoke names new leaders in media, AI and client accounts
Lilly forges $3.35bn alliance with China's InnoCare
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
Mirum puts Hepcludex in its sights with hep D readout
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
Novo, Lilly unleash dueling GLP-1 datasets at EASD in Milan
Packaging Compliance Labs Enters Pharmaceutical Testing Market with Dedicated Lab and Expert Leadership
Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit
PhRMA locks in former House Majority Leader Cantor as next CEO
Public Comment Sought on Draft FDA Petition to Require a Warning Label on Raw Milk Cheese - All Comments Due by October 9
Publication of ROADS Phase 3 Clinical Trial Data in Journal of Clinical Oncology Recommends GammaTile® as a New Standard-of-Care Option for Newly Diagnosed Operable Brain Metastases1
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
Summit snags $2B investment from AstraZeneca, clearing financial overhang
Telix to buy radiopharma rival ITM for $1.65bn upfront
uniQure falls on long-term Huntington's gene therapy data
US details rules for pharmaceutical tariff exemptions
UTR Therapeutics Inc. Announces U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for UTRxMYCN M1-14
VertigoDx Secures FDA 510(k) Clearance for SmartVertigo® Point-of-Care Vestibular Diagnostic System
White House looks to ramp up domestic generic manufacturing
XYone Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of XYA02(AT2021), a Novel Antibody Drug Conjugate targeting MUC1-C
6 immunology targets to sustain a mammoth I&I market
As the race to harness CAR-T cells for autoimmune diseases hits a rough patch, Adicet Bio is reporting an early sign of efficacy in lupus, with remissions in an early-stage trial.
AI is eroding the barriers that kept biological weapons rare
BioNTech to close sites in Germany after failed sale
BRC Therapeutics Joins FDA and EMA Regulators at Workshop Advancing the Future of Botanical Drug Development
FDA Approves First Treatment for MCT8 Deficiency
FDA intends to evaluate changes to the PMTA regulatory framework
FDA nod for Mirum's Atebrioz makes 3 options for ultra-rare bone disease
Fuse Oncology and Associated Medical Professionals of NY Launch Proof of Concept for End-to-End Radiation Oncology Workflow in Urology
Insera Therapeutics, Inc. Receives U.S. FDA 510(k) Clearance for the CLEAR™ Aspiration System Featuring Cyclical Aspiration
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
Kodiak Sciences' stock doubled after the biotech reported a pivotal-trial win for an eye disease drug candidate it had previously set aside, reviving the programme's path toward a regulatory filing.
Eli Lilly's weight loss and diabetes medicines have become a dominant force in the market, but access varies widely around the world. A new initiative aims to take GLP-1s to lower-income nations by 2040.
Lupin has received tentative approval from the U.S. FDA for Apixaban Oral Suspension 1.25 mg/mL, an oral liquid formulation of the active ingredient in Eliquis that offers an alternative administration option for adults requiring anticoagulation therapy.
Merck continues to diversify its cancer efforts as the clock ticks down on Keytruda's patent, picking up rights to a preclinical oncology asset in a deal that could exceed $2 billion.
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat
A phase 3 trial of Mirum Pharmaceuticals' chronic hepatitis delta virus drug candidate has hit its primary endpoint, furthering the biotech's efforts to enter a space recently colonized by Gilead Sciences.
MSD and Daiichi Sankyo's regulatory efforts for their ADCs for cancer have stuttered again, with a withdrawn filing for lung cancer candidate I-DXd.
Risk from toxic metals can persist months after wildfires, Maui study finds
Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.
Roche's Gazyva secures FDA nod in 2nd autoimmune indication
BARDA has awarded Scynexis a contract worth up to $214 million for development of a treatment for invasive fungal infections. The non-dilutive funding includes nearly $18.5 million up front to push antifungal candidate SCY-247 into phase 2, with options to extend the contract for up to ten years.
A new study suggests long-read 'nanopore' sequencing could transform the diagnosis of inherited diseases and unlock new insights for drug discovery.
After vaulting into the clinic by licensing a fusion protein last month, Tolerance Bio has continued to strengthen its thymus-focused pipeline by picking up an anti-IL-33 drug from Tanabe Pharma.
Fondazione Telethon and UCSF Benioff Children's Hospitals say the hospital is the first U.S. qualified treatment center contracted to administer the individualized gene therapy WASKYRA.
UCSF Benioff Children's Hospitals Become the First US Qualified Treatment Center Contracted to Administer Individualized Gene Therapy WASKYRA®
US drugmakers turn to China for licensing deals
AbbVie's JUVMO (tavapadon) is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease. The once-daily tablet works with or without levodopa, and the approval is supported by the Phase 3 TEMPO programme.
For partnerships, media inquiries, or general updates, reach out to us:
Email: info@openbionews.com
Phone: 925 394-6606